Sanofi signs exclusive license for Maze Therapeutics' in-development Pompe disease treatment
MLex Summary: Sanofi has signed an exclusive worldwide license for Maze Therapeutics' in-development treatment for the genetic condition known as Pompe disease, according to a press release from Maze. The deal...To view the full article, register now.
Already a subscriber? Click here to view full article